Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on high salt diet-Reference-Cited by-同舟云学术

Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on high salt diet

Published:2022-02 Issue: Volume:146 Page:112606
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Zeng Shufei,Delic Denis,Chu Chang,Xiong Yingquan,Luo Ting,Chen Xiaoyi,Gaballa Mohamed M.S.,Xue Yao,Chen Xin,Cao Yaochen,Hasan Ahmed A.,Stadermann Kai,Frankenreiter Sandra,Yin Lianghong,Krämer Bernhard K.,Klein Thomas,Hocher Berthold

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference33 articles.

1. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases;Wanner;Diabetologia,2018

2. Development of SGLT1 and SGLT2 inhibitors;Rieg;Diabetologia,2018

3. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N. Engl. J. Med.,2015

4. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;N. Engl. J. Med.,2016

5. Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression;Abbas;Naunyn Schmiede Arch. Pharm.,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: Lessons from preclinical studies;Chemico-Biological Interactions;2024-11

2. Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases;Physiological Research;2024-08-31

3. Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet;Biomedicine & Pharmacotherapy;2024-05

4. SGLT-2 inhibitors as novel treatments of multiple organ fibrosis;Heliyon;2024-04

5. SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback;Kidney360;2024-03-25